[1]崔雯锦,胡欣,韦晓,等.免疫检查点抑制剂诱发甲状腺功能紊乱的研究进展[J].国际内分泌代谢杂志,2021,41(01):33-37.[doi:10.3760/cma.j.cn121383-20200909-09019]
　Cui Wenjin,Hu Xin,Wei Xiao,et al.Progress in immune checkpoint inhibitors induced thyroid dysfunction[J].International Journal of Endocrinology and Metabolism,2021,41(01):33-37.[doi:10.3760/cma.j.cn121383-20200909-09019]
点击复制

免疫检查点抑制剂诱发甲状腺功能紊乱的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年01期
页码:
33-37
栏目:
甲状腺疾病专题
出版日期:
2021-01-20

文章信息/Info

Title:
Progress in immune checkpoint inhibitors induced thyroid dysfunction
作者:
崔雯锦; 胡欣; 韦晓; 陈国芳; 刘超
南京中医药大学附属中西医结合医院内分泌科,江苏省中医药研究院内分泌科 210028
Author(s):
Cui Wenjin;  Hu Xin;  Wei Xiao;  Chen Guofang;  Liu Chao.
Department of Endocrinology, the Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China
关键词:
免疫检查点抑制剂;  免疫相关不良事件;  甲状腺功能紊乱
Keywords:
Immune checkpoint inhibitors;  Immune-related adverse events;  Thyroid dysfunction
DOI:
10.3760/cma.j.cn121383-20200909-09019
摘要:
随着免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在肿瘤领域的广泛应用,其诱发的免疫相关不良事件(immune-related adverse events,irAEs)愈发多见。甲状腺功能紊乱在ICIs治疗过程中最为常见,包括甲状腺毒症和甲状腺功能减退,但常因其症状轻微且缺乏特异性易被漏诊或误诊。掌握ICIs相关甲状腺功能紊乱的发病特点和诊断治疗要点,有助于临床医师对肿瘤免疫治疗相关的常见内分泌不良反应及时识别和处理。
Abstract:
With the widely use of immune checkpoint inhibitors(ICIs)in the treatment of tumors, the prevalence of immune-related adverse events(irAEs)induced by ICIs is increasingly widespread. Thyroid dysfunction is the most common adverse event, including thyrotoxicosis and hypothyroidism, but the mild and atypical symptoms may lead to missed or delayed diagnosis. Understanding the characteristics, diagnosis and treatment of ICIs-related thyroid disorder may play an important role in the management of ICIs-related endocrine dysfunction.

参考文献/References:

[1] Brahmer JR,Lacchetti C,Schneider BJ,et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American Society of Clinical Oncology Clinical Practice Guideline[J].J Clin Oncol,2018,36(17):1714-1768.DOI:10.1200/JCO.2017.77.6385.
[2] Arima H,Iwama S,Inaba H,et al. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors:clinical guidelines of the Japan Endocrine Society[J].Endocr J,2019,66(7):581-586.DOI:10.1507/endocrj.EJ19-0163.
[3] Chang LS,Barroso-Sousa R,Tolaney SM,et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints[J]. Endocr Rev,2019,40(1):17-65.DOI:10.1210/er.2018-00006.
[4] Barroso-Sousa R,Barry WT,Garrido-Castro AC,et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens:a systematic review and meta-analysis[J].JAMA Oncol,2018,4(2):173-182.DOI:10.1001/jamaoncol.2017.3064.
[5] Michot JM,Bigenwald C,Champiat S,et al. Immune-related adverse events with immune checkpoint blockade:a comprehensive review[J].Eur J Cancer,2016,54:139-148.DOI:10.1016/j.ejca.2015.11.016.
[6] Lee H,Hodi FS,Giobbie-Hurder A,et al. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy[J].Cancer Immunol Res,2017,5(12):1133-1140.DOI:10.1158/2326-6066.CIR-17-0208.
[7] Byun DJ,Wolchok JD,Rosenberg LM,et al. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies[J].Nat Rev Endocrinol,2017,13(4):195-207.DOI:10.1038/nrendo.2016.205.
[8] Maekura T,Naito M,Tahara M,et al. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer[J].In Vivo,2017,31(5):1035-1039.DOI:10.21873/invivo.11166.
[9] de Moel EC,Rozeman EA,Kapiteijn EH,et al. Autoantibody development under treatment with immune-checkpoint inhibitors[J].Cancer Immunol Res,2019,7(1):6-11.DOI:10.1158/2326-6066.CIR-18-0245.
[10] Zhu C,Ma J,Liu Y,et al. Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease[J].J Clin Endocrinol Metab,2012,97(3):943-950.DOI:10.1210/jc.2011-2003.
[11] Liu Y,Yuan X,Li X,et al. Constitutive changes in circulating follicular helper T cells and their subsets in patients with Graves' disease[J].J Immunol Res,2018,2018:8972572.DOI:10.1155/2018/8972572.
[12] 方晨,郭鹤鸣,黄韵,等. 警惕肿瘤免疫治疗的内分泌系统不良反应[J]. 国际内分泌代谢杂志,2019,39(5):327-331,336.DOI:10.3760/cma.j.issn.1673-4157.2019.05.010.
[13] Francisco LM,Sage PT,Sharpe AH. The PD-1 pathway in tolerance and autoimmunity[J].Immunol Rev,2010,236:219-242.DOI:10.1111/j.1600-065X.2010.00923.x.
[14] Rowshanravan B,Halliday N,Sansom DM. CTLA-4:a moving target in immunotherapy[J].Blood,2018,131(1):58-67.DOI:10.1182/blood-2017-06-741033.
[15] Chalan P,Di Dalmazi G,Pani F,et al. Thyroid dysfunctions secondary to cancer immunotherapy[J].J Endocrinol Invest,2018,41(6):625-638.DOI:10.1007/s40618-017-0778-8.
[16] Mengos AE,Gastineau DA,Gustafson MP. The CD14+HLA-DRlo/neg monocyte:an immunosuppressive phenotype that restrains responses to cancer immunotherapy[J].Front Immunol,2019,10:1147.DOI:10.3389/fimmu.2019.01147.
[17] Delivanis DA,Gustafson MP,Bornschlegl S,et al. Pembrolizumab-induced thyroiditis:comprehensive clinical review and insights into underlying involved mechanisms[J].J Clin Endocrinol Metab,2017,102(8):2770-2780.DOI:10.1210/jc.2017-00448.
[18] Iwama S,De Remigis A,Callahan MK,et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody[J].Sci Transl Med,2014,6(230):230-245.DOI:10.1126/scitranslmed.3008002.
[19] Thompson JA,Schneider BJ,Brahmer J,et al. Management of immunotherapy-related toxicities,Version 1.2019[J].J Natl Compr Canc Netw,2019,17(3):255-289.DOI:10.6004/jnccn.2019.0013.
[20] McMillen B,Dhillon MS,Yong-Yow S. A rare case of thyroid storm[J].BMJ Case Rep,2016,2016:10.1136.DOI:10.1136/bcr-2016-214603.
[21] Ha J,Jo K,Kang B,et al. Cholestyramine use for rapid reversion to euthyroid states in patients with thyrotoxicosis[J].Endocrinol Metab(Seoul),2016,31(3):476-479.DOI:10.3803/EnM.2016.31.3.476.
[22] Khan U,Rizvi H,Sano D,et al. Nivolumab induced myxedema crisis[J].J Immunother Cancer,2017,5:13.DOI:10.1186/s40425-017-0213-x.
[23] Osorio JC,Ni A,Chaft JE,et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J].Ann Oncol,2017,28(3):583-589.DOI:10.1093/annonc/mdw640.
[24] Kim HI,Kim M,Lee SH,et al. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer[J].Oncoimmunology,2017,7(1):e1375642.DOI:10.1080/2162402X.2017.1375642.

相似文献/References:

[1]方晨 郭鹤鸣 黄韵 陈小红 李思诚 刘翠平 胡吉.警惕肿瘤免疫治疗的内分泌系统不良反应[J].国际内分泌代谢杂志,2019,39(05):327.[doi:10.3760/cma.j.issn.1673-4157.2019.05.010]
　Fang Chen,Guo Heming,Huang Yun,et al.Be aware of endocrinological side effects of cancer immunotherapy[J].International Journal of Endocrinology and Metabolism,2019,39(01):327.[doi:10.3760/cma.j.issn.1673-4157.2019.05.010]
[2]崔雯锦,陈国芳,刘超.免疫检查点抑制剂相关内分泌疾病诊治研究进展[J].国际内分泌代谢杂志,2021,41(02):116.[doi:10.3760/cma.j.cn121383-20200331-03086]
　Cui Wenjin,Chen Guofang,Liu Chao..Progress in the diagnosis and treatment of immune checkpoint inhibitors related endocrine diseases[J].International Journal of Endocrinology and Metabolism,2021,41(01):116.[doi:10.3760/cma.j.cn121383-20200331-03086]

备注/Memo

备注/Memo:
通信作者:陈国芳,Email:chenguofang9801@126.com; 刘超,Email:liuchao@nfmcn.com 基金项目:国家自然科学基金(81800756); 江苏省第十六批“六大人才高峰”项目(WSN-035); 国家中医药管理局重大疑难疾病中西医临床协作试点项目(2018); 江苏省中医药领军人才项目(SLJ0209)
更新日期/Last Update: 2021-01-20